IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: 7498 Conf. No.:

Wolfgang E. BERDEL et al.

Art Unit: 1647
Examiner: Marianne P. Allen Appln. No.: 10/569,076

Atty. Docket: P30712US00 / 20490.003 Filing Date: August 23, 2006

For: Fusion Peptides, and Use Thereof in Antivascular Tumor Therapy

Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO/SB/08a. Copies of the listed documents are attached.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, authorization to charge the statutory fee of \$180 to counsel's deposit account is given in the accompanying transmittal letter.

Respectfully submitted,

Filed: November 17, 2008

Kristan L. Lansbery (Reg. No. 53)

David R. Marsh (Reg. No. 41,408)

ARNOLD & PORTER LLP

Attn: IP Docketing

555 Twelfth Street, N.W. Washington, DC 20004-1206

Tel.: 202.942.5000 Fax: 202.942.5999